2-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-N-[4-(9Hpurin-6-yloxy)-phenyl]-acetamide | 936099-51-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-N-[4-(9Hpurin-6-yloxy)-phenyl]-acetamide
• 英文别名: 2-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-N-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]acetamide
• CAS: 936099-51-3
• 化学式: C₂₅H₁₉F₃N₆O₂
• 分子量: 492.46
• InChiKey: FHARENXOZXVKTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  97.7
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
  申请人：Nagle Advait

  公开号：US20100324062A1

  公开（公告）日：2010-12-23

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Aurora-A, Axl, BMX, CHK2, c-RAF, cSRC, Fes, FGFR3, Flt3, IKKα, IR, JNK2α2, Lck, Met, MKK6, MST2, p70S6K, PDGFRα, PKA, PKD2, ROCK-II, Ros, Rsk1, SAPK2α, SAPK2β, SAPK3, SAPK4, Syk, Tie2 and TrkB kinases.

  本发明提供了一类新型化合物，包括这些化合物的药物组合物，并使用这些化合物的方法来治疗或预防与异常或失调激酶活性相关的疾病或障碍，特别是涉及Abl、Bcr-Abl、AuroRA-A、Axl、BMX、CHK2、c-RAF、cSRC、Fes、FGFR3、Flt3、IKKα、IR、JNK2α2、Lck、Met、MKK6、MST2、p70S6K、PDGFRα、PKA、PKD2、ROCK-II、Ros、Rsk1、SAPK2α、SAPK2β、SAPK3、SAPK4、Syk、Tie2和TrkB激酶异常激活的疾病或障碍。
• [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DES KINASES DES PROTEINES
  申请人：IRM LLC

  公开号：WO2007053343A2

  公开（公告）日：2007-05-10

  [EN] The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-Abl, Aurora- A, AxI, BMX, CHK2, c-RAF, cSRC, Fes, FGFR3, Flt3, IKKa, IR, JNK2a2, Lck, Met, MKK6, MST2, p70S6K, PDGFRa, PKA, PKD2, ROCK-II, Ros, Rskl, SAPK2a, SAPK2ß, SAPK3 SAPK4, Syk, Tie2 and TrkB kinases.
  [FR] L'invention concerne une nouvelle classe de composés, des compositions pharmaceutiques qui comprennent ces composés et des procédés d'utilisation de ces composés pour traiter ou prévenir des maladies ou des affections associés à une activité anormale ou dérégulée des kinases et en particulier les maladies ou affections associés à une activation anormale des kinases d'AbI, de Bcr-Abl, d'Aurora-A, d'AxI, de BMX, de CHK2, de c-RAF, de cSRC, de Fes, de FGFR3, de Flt3, d'IKKa, d'IR, de JNK2a2, de Lck, de Met, de MKK6, de MST2, de p70S6K, de PDGFRa, de PKA, de PKD2, de ROCK-II, de Ros, de Rskl, de SAPK2a, de SAPK2ß, de SAPK3, de SAPK4, de Syk, de Tie2 et de TrkB.